Professor Eden is an expert on transfer pricing and multinational enterprises (MNEs), with decades of experience consulting to MNEs, governments, and international organizations on transfer pricing and MNE strategies and structures. In transfer pricing matters, she has served as an expert witness – in cases that include Coca-Cola Co. v. Commissioner and In re: Nortel Networks – and filed numerous expert reports. Professor Eden has taught courses on transfer pricing, MNEs, and the economics of international business, and founded the Transfer Pricing Aggies program at Texas A&M University, which has trained hundreds of graduate students. She has extensive research experience in areas such as transfer pricing and MNE strategies in the digital economy, and citations to her publications place her in the top 2% of research scientists worldwide. Professor Eden has authored several books, including Taxing Multinationals: Transfer Pricing and Corporate Income Taxation in North America, Multinationals in North America, The Economics of Transfer Pricing, and Research Methods in International Business. She is a frequent speaker at transfer pricing and tax conferences, as well as a former president and dean of the Fellows of the Academy of International Business. She is a currently a member of the United Nations Tax Committee’s Subcommittee on Transfer Pricing.

Mr. McLean specializes in applying finance and economics to problems in complex business litigation, including securities, valuation, tax, and intellectual property (IP) matters. His experience spans several industries, from banking, insurance, and high tech to telecommunications and health care. He has served as an expert witness, and has provided assistance in many phases of litigation, including development, presentation, and review of pretrial discovery; preparation of testimony; and critique of analyses of opposing experts.

Mr. McLean’s case work has included general damages analyses, lost profit and reasonable royalty calculations related to IP misappropriation, and assessments of fiduciary duties and investment management. In addition, he has evaluated the economic characteristics and risk transfer of a range of financial instruments, such as private mortgage insurance, subprime loans, and preferred equity in a new venture. He has led large case teams in a number of high-profile matters, including consulting to the US Department of Justice (DOJ) regarding the financial issues involved in tribal trust fund disputes, and supporting counsel for a large electronics manufacturer in litigation associated with features on smartphones and tablets.

In addition, Mr. McLean has presented on topics related to damages assessment and patents. He has also worked with entrepreneurial companies, helping to develop financial projections, business plans, and marketing strategies.

Mr. Bodington specializes in the business and finance aspects of the electric power industry. He is the founder of a boutique investment banking firm that has provided M&A, financing, and restructuring advisory services to the energy sector for more than 25 years. Mr. Bodington has played a key role in more than 100 transactions with an aggregate value of more than $7 billion. In these engagements, he has led the purchase and sale of interests in power projects; arranged debt and equity financing for energy projects in development, construction, and operation; and advised owners and lenders on various capitalization, value, repayment, restructuring, and management issues. His clients include industrial companies, independent power companies, equity investors, lenders, utility affiliates, and regulated utilities. 

Mr. Bodington is also a seasoned expert witness who has provided testimony for clients on finance and damages issues. Prior to founding Bodington & Company, he spent eight years with Bechtel Group and four years with an international management consulting firm. Mr. Bodington is the author of more than 50 articles on a variety of economic and financial topics relevant to the energy sector. He holds Financial Industry Regulatory Authority (FINRA) Series 7, 24, 63, 79, and 99 licenses.

Professor Ketcham is a health care economist with over two decades of experience researching, teaching, and consulting. His areas of expertise include pharmaceutical advertising and promotion, pharmacy benefit managers, health insurance, consumer decision making, physician decision making, hospital pricing, provider incentive programs and payment methods, fair market valuation, employee benefits, and valuation of changes in morbidity and mortality. From 2022 to 2024, Professor Ketcham took a leave from the W.P. Carey School of Business to serve as senior economic advisor to the employee benefits team of a major high-tech company. He has consulted for and collaborated with several large pharmaceutical firms, Banner Health, CVS Caremark, Symphony Health Solutions, the Centers for Medicare & Medicaid Services, the US Department of Health and Human Services, and the US Environmental Protection Agency. Professor Ketcham’s research has been published in journals such as the American Economic Review, The Review of Economic Studies, the American Journal of Health Economics, and Health Affairs. He has served as principal investigator on multiple grants, including federal government grants to study physician decision making, incentive programs, and provider pricing.

Dr. Dawson specializes in applying economics and finance to complex problems in business litigation, including intellectual property (IP), false advertising, securities, and finance matters. Dr. Dawson’s experience spans several industries, from medical devices and high tech to telecommunications and accounting. Dr. Dawson has consulted to counsel in all phases of the litigation process, including understanding complex claims, assisting with fact and expert discovery, and providing trial support. She has served as an expert witness on matters involving licensing, false advertising, and breach of contract. Dr. Dawson’s case work has involved complex data analysis; development of financial models; general damages assessment; evaluation of lost profits, royalty, and other damages remedies in IP and false advertising matters; ascertainment of loss causation and damages in securities fraud matters; and financial statement analyses. Dr. Dawson has spoken at various conferences and served as a panelist on the topics of platform economics and IP damages. Dr. Dawson has been recognized among the top economic experts for IP matters by Intellectual Asset Management (IAM) in the IAM Patent 1000, which identifies leading patent professionals around the globe.

Read Na's profile

Professor Rossiter is an expert in health economics who has testified or served as an expert in the following areas: competition in the financing and delivery of health services; reimbursement economics, especially for Medicare, Medicare Advantage, and Medicaid; managed care organizations; prescription medicines; survey research; and health information analytics. Professor Rossiter is the former secretary of health and human resources for the Commonwealth of Virginia. In that role, he was responsible for over 15,000 employees in 13 agencies (including 10 state mental hospitals), brought major information technology projects in the Secretariat to national prominence, and made major reforms in Virginia Medicaid. He also served as deputy for policy to the Administrator of the Centers for Medicare and Medicaid Services (CMS). As deputy, he created and directed a new payment system for US hospitals under Medicare, was responsible for the CMS strategic plan, and formulated all agency policy initiatives through the federal legislative process.

Prior to joining the William & Mary faculty, Professor Rossiter was a professor of health administration at Virginia Commonwealth University. He served on the board of regents of the National Library of Medicine, National Institutes of Health; on the board of directors of AcademyHealth; and as chair of the board of directors of the Coalition for Health Services Research, the lobbying arm of AcademyHealth, during the passage of the Affordable Care Act. He has also served on numerous advisory groups, including the National Advisory Council for Healthcare Research and Quality, and is currently a trustee and chair of the Williamsburg Health Foundation. Professor Rossiter is the author or editor of 15 books, and the author of over 50 journal articles on health economics and the role of competition in the financing and delivery of health services.

Professor Levinsohn is an expert in antitrust, industrial organization, and econometrics. He has provided expert reports and testimony in several landmark antitrust and regulatory matters, including In re: TFT-LCD (Flat Panel) Antitrust Litigation, In re: Vitamins Antitrust Litigation, In re: New Motor Vehicles Canadian Export Antitrust Litigation, and the Tobacco Master Settlement Agreement proceedings. He has also consulted to numerous foreign governments and international organizations.

Professor Levinsohn conducts research in industrial organization, applied econometrics, international economics, and development economics. He has served on the editorial boards of American Economic Review, The Review of Economics and Statistics, the Journal of International Economics, and the Journal of Economic Literature. Prior to joining the Yale faculty, Professor Levinsohn was the J. Ira and Nicki Harris Family Professor of Public Policy at the Gerald R. Ford School of Public Policy at the University of Michigan.

Dr. DerSarkissian’s expertise includes the application of epidemiologic methods to real-world evidence (RWE) generation in support of product registration, post-approval safety studies, and health economics and outcomes research (HEOR). She has served as an expert witness in litigation and has a wide range of experience in pharmacoepidemiology, biostatistics, and observational data analysis, including in studies on causal methods. Dr. DerSarkissian has provided regulatory and strategic consulting on drug and medical device registration and conducted RWE studies related to US Food and Drug Administration (FDA) and European Medicines Agency (EMA) submissions. She has conducted cost-effectiveness and comparative effectiveness studies; examined treatment patterns, drug adherence, health care resource utilization and costs, and clinical outcomes; assessed direct medical and indirect productivity costs of a disease burden; and assessed patient-reported quality of life and the humanistic burden of a disease. Dr. DerSarkissian has used data from electronic medical records, clinical trials, commercial insurance claims, patient surveys, and medical chart review studies in disease areas that include obesity; HIV/AIDS; cardiovascular diseases; schizophrenia; autoimmune, neurologic, and rare hereditary disorders; and many types of cancer. She has presented her research at conferences on epidemiology and health services, and published articles in a number of peer-reviewed journals. Dr. DerSarkissian is an adjunct assistant professor in the epidemiology department at the UCLA Fielding School of Public Health.

Read Maral's profile

Pierre Cremieux, CEO of Analysis Group, has a broad range of expertise in health economics, antitrust, statistics, and labor economics. He has consulted to numerous clients in the US and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings.

Dr. Cremieux has served as an expert and supported other experts in both litigation and non-litigation matters on antitrust issues; general commercial claims; contractual disputes; and a number of labor-related matters in a variety of industries, including high tech, pharmaceuticals, biotech, financial products, consumer products, and commodities. He has assessed the evaluation of damages on a class-wide basis in some of the largest class action matters in recent years.

His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals including the George Mason Law Review, the American Bar Association Economics Committee Newsletter, The Review of Economics and Statistics, the Journal of Health Economics, Industrial and Labor Relations Review, the Journal of Clinical Oncology, and the American Journal of Managed Care. Dr. Cremieux's research has been cited in leading media outlets including The Wall Street Journal and Forbes.

Dr. Cremieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics, and statistics, in both the United States and Canada. He has also been invited to teach courses on economics, statistics, health care, and antitrust at various schools including McGill University, Boston University, Harvard Medical School, and Yale's School of Management.

Prior to joining Analysis Group in 1997, Dr. Cremieux spent five years as a professor at the University du Québec à Montréal, and served as an adjunct professor from 1997 to 2018.

Professor Kinch is a drug development expert specializing in cancer, immunological, and infectious diseases. His research focuses on combining cutting-edge science and entrepreneurship to improve public health. During his tenure at Washington University in St. Louis, Professor Kinch founded the Center for Research Innovation in Biotechnology (CRIB). At Long Island University (LIU), he directed CRIB, which uses tools such as the Clinical Drug Experience Knowledgebase (CDEK) to assess trends in drug discovery and development. Professor Kinch also co-founded the Center for Drug Discovery (CDD) to identify and underwrite the university’s most promising drug discovery projects. He has been issued more than a dozen US patents, published more than 100 patent applications, and written several books and book chapters on the commercialization of biopharmaceutical innovation, as well as other aspects of drug development. Professor Kinch has published widely in peer-reviewed journals, including Drug Discovery Today, Science, Cell Chemical Biology, and Biotechnology Law Report, and his research has been profiled in media outlets such as The Wall Street Journal, NPR, CBS News, and The New York Times. Prior to his positions at LIU and Washington University, he was the managing director of the Yale Center for Molecular Discovery. Professor Kinch has also taught at Johns Hopkins University and Purdue University, and held senior scientific research positions at Functional Genetics and MedImmune. He has served on the board of the American Cancer Society and on scientific advisory boards for several biopharmaceutical companies.

Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has extensive experience with issues involving competition, intellectual property, marketing, pricing, and valuation with a focus on pharmaceuticals and the health care industry. His analyses have addressed issues of pricing, profitability, and payment flows at all levels of the distribution chain for pharmaceuticals and other health care products and services. He has evaluated and provided expert testimony on questions of causation, damages, class certification, and valuation in a variety of health care cases, including cases involving allegations of False Claims Act (FCA) and Anti-Kickback Statute (AKS) violations, Lanham Act matters, and antitrust matters. In addition to his work in litigation, Dr. Mortimer has assisted pharmaceutical and medical device manufacturers on pricing and contracting issues and authored several public policy studies related to legislation establishing a biosimilar approval pathway, biosimilar competition, pharmaceutical pricing, generic drug competition and the role of authorized generic entry, and paragraph IV abbreviated new drug application (ANDA) filings. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.

Professor Pindyck is a leading industrial organization economist and testifying witness in the areas of antitrust and intellectual property. His research and writing have covered topics in microeconomics and industrial organization, the behavior of resource and commodity markets, financial markets, and econometric modeling and forecasting. His recent work in economics and finance has examined the determinants of market structure and market power, the dynamics of commodity spot and futures markets, criteria for investing in risky projects, the role of R&D, and the value of patents. He has received many academic honors, including several awards for outstanding teaching, and holds senior editorial positions with a number of publications. Professor Pindyck has consulted to dozens of public and private organizations, including the Federal Trade Commission, IBM, and AT&T, and has been deposed and/or testified in over a dozen cases in diverse industries such as food, energy, software, medical devices, and airlines. He has worked with Analysis Group on many of these cases, including the Lotus v. Borland litigation, in which Professor Pindyck used econometric modeling techniques to identify the economic value of various attributes and isolated the value of the infringing features. He also worked with Analysis Group in a major litigation matter involving price-fixing allegations, in which he examined allegations of accumulation of buying power and the resulting effects on negotiations with suppliers.

Professor Forbes has over 20 years of experience researching a wide variety of economic issues in antitrust, industrial organization, and organizational economics. Her work includes topics such as price and non-price competition, vertical relationships, cross-industry spillovers, contracting, disclosure regulations, and switching costs, in industries such as airlines, hospitality, health insurance, and manufacturing. Professor Forbes’ research has been published in a number of economics and management journals, including the American Economic Review, Management Science, the RAND Journal of Economics, the American Economic Journal, the Journal of Public Economics, The Journal of Industrial Economics, the International Journal of Industrial Organization, and The Journal of Law, Economics, & Organization. She is a coeditor of Economic Inquiry and associate editor at the Journal of Economics and Statistics. She has served on the editorial board of the Journal of the Air Transport Research Society and on the executive committee of the Society for Institutional & Organizational Economics. Prior to joining the Tufts faculty, she held faculty appointments at the University of California, San Diego and Case Western Reserve University. She has also been a visiting professor at the MIT Sloan School of Management and has worked as an economist at the US Department of Transportation. Professor Forbes has received grants and fellowships from the National Science Foundation, the Alfred P. Sloan Foundation, and the German National Merit Foundation.

Professor Bucklin is an award-winning research specialist in the quantitative analysis of customer purchase behavior. He is an expert on applied choice models in marketing, channels of distribution, and pricing policies. Professor Bucklin has testified or been deposed in numerous cases involving antitrust and damages issues and most recently served as an expert in the Google AdWords litigation. In his current consulting work, Professor Bucklin focuses on quantitative tools to improve corporate marketing decision making and analysis of the variables involved in consumer choice. He has published extensively on topics related to website browsing, e-commerce purchase behavior, and marketing models. His articles have appeared in the Journal of Marketing Research, Marketing Science, the Journal of Retailing, and Marketing Letters: A Journal of Research in Marketing. He also serves on the editorial board of Marketing Letters. Professor Bucklin previously worked as a consultant at Bain & Company and as a business journalist for The Washington Post.

Professor Klausner teaches courses on corporate law, corporate governance, business transactions, and regulation of financial institutions. In recent years, most of his writing has been on corporate governance. He maintains a database on securities class actions and SEC enforcement actions, and has written papers and blog posts based on that database. In addition, Professor Klausner is currently writing a book and producing an online course called Deals: The Economic Foundations of Business Transactions.

Before beginning his academic career, Professor Klausner practiced law in Washington, DC, and Hong Kong. He was a White House fellow from 1989 to 1990, a law clerk for Judge David Bazelon on the United States Court of Appeals for the District of Columbia Circuit in 1981-82, and a law clerk for Justice William Brennan on the United States Supreme Court.

Professor Savitz focuses his epidemiological research on a wide range of public health issues, from the health effects of environmental agents in the workplace and community to a wide range of reproductive health outcomes. He has served as principal investigator on more than three dozen public health studies, including as one of three epidemiologists to evaluate the probable causal link between exposure to perfluorooctanoic acid and the development of certain diseases. Professor Savitz submitted an expert report on behalf of the plaintiffs at the class certification stage of a litigation matter and has consulted on a wide range of issues related to both environmental and reproductive epidemiology. He is the author of more than 300 journal articles and has edited or authored three books, including Interpreting Epidemiologic Evidence: Connecting Research to Applications. Professor Savitz has served as the editor of Epidemiology and the American Journal of Epidemiology, a member of the Epidemiology and Disease Control Study Section of the National Institutes of Health, president of the Society for Epidemiologic Research and the Society for Pediatric and Perinatal Epidemiologic Research, and North American regional councilor for the International Epidemiological Association. He is a member of the National Academy of Medicine and served as vice president for research at Brown University.

Dr. Duh, Chief Epidemiologist at Analysis Group, specializes in real-world evidence (RWE) generation for product registration, post-approval safety studies, and health economics and outcomes research (HEOR) of pharmaceuticals, vaccines, and regenerative biotherapeutics. She has led over 50 projects for new molecular entity approvals and product label expansion applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as health technology assessment (HTA) research for submissions to national payers such as the Centers for Medicare and Medicaid Services (CMS) in the US and the UK’s National Institute for Health and Care Excellence (NICE). Her extensive research has appeared in over 315 peer-reviewed publications.

Her work also extends to pharmaceutical liability litigation and securities fraud litigation related to adverse drug events that allegedly led to product recalls, market withdrawals, black box warnings, and FDA limited access programs.

Dr. Duh is an adjunct research associate in the Biostatistics department at the Harvard T.H. Chan School of Public Health. She served as a chairperson of drug safety and epidemiology for the Drug Information Association (DIA) and was an adjunct assistant professor of pharmacoeconomics and pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health’s (FNIH’s) Observational Medical Outcomes Partnership (OMOP). She has served as a peer reviewer for several journals, including PharmacoEconomics, the American Journal of Health-System Pharmacy, Chest, Pharmacoepidemiology and Drug Safety, the American Journal of Kidney Diseases, and Therapeutics and Clinical Risk Management. Dr. Duh is also an elected member of the American Society of Hematology (ASH) and a member of the American Society of Clinical Oncology (ASCO), the International Society of Pharmacoepidemiology (ISPE), and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

View Dr. Duh's selected publications on the Harvard Catalyst website

Professor Reibstein’s research focuses on competitive marketing strategies, metrics, and product line decisions, among other topics. He has provided marketing management education and consulting research to companies in the consumer goods, pharmaceutical, and oil and gas industries, among others. His consulting activities have included numerous applications of conjoint analysis and other survey techniques in engagements spanning a wide range of products. Professor Reibstein has submitted expert reports and provided testimony on marketing and marketing research in several litigation matters, including analyses of smartphone features in a patent dispute, health claims in a false advertising dispute, and pharmaceutical detailing in a co-marketing dispute.

His recent work includes assessing strategies to address competitors’ reactions to marketing actions and developing metrics that link marketing decisions to financial consequences, which was published in his book, Marketing Metrics: The Definitive Guide to Measuring Marketing Performance. Professor Reibstein is also the author or coauthor of numerous books and chapters in books on subjects including competitive marketing strategy, global branding, and marketing performance measurement. Professor Reibstein has also written several papers on conjoint analysis and its validity and reliability. His research has been published in leading academic journals, including Marketing Science, the Journal of Marketing Research, and the International Journal of Research in Marketing.  

Professor Reibstein has been honored with more than 30 teaching and publishing awards, including the John S. Day Distinguished Alumni Academic Service Award from Purdue University’s Krannert School of Management. He has served as the chairman of the American Marketing Association board of directors and as the executive director of the Marketing Science Institute.

Mr. Darling consults to clients and provides expert testimony to address litigation, strategy, regulatory, and policy questions in a wide range of antitrust and competition, class certification, health care, energy, and environmental matters. He has submitted and supported expert testimony before US district and appellate courts, state utility commissions, siting boards, and federal agencies. He has also assisted clients with responses to government investigations and presented findings before US Attorneys’ Offices, state attorneys general, and the US Drug Enforcement Administration.

In the areas of health care and antitrust, Mr. Darling has extensive experience supporting clients on issues related to discovery and data production, class certification, patent infringement, market definition and market power, and competitive effects in pharmaceutical and life sciences matters involving patent infringement issues, reverse payment settlements, and product hop allegations. He has also designed and implemented customized suspicious order monitoring (SOM) and loss prevention programs for controlled substances, and has experience in False Claims Act and Anti-Kickback Statute litigation cases, including analyses of causation and damages calculations.

Mr. Darling is also an expert on electricity, oil, and natural gas pricing, markets, and infrastructure. His consulting work on behalf of utilities, state and regional organizations, and global companies includes projects related to cost/benefit analyses of new plant construction and retirements; ratepayer and bill impacts; environmental effects of emissions and pollution controls; economic impacts of energy projects, mergers, and policies; natural gas, biomass, and other market studies; and climate change matters including decarbonization policy proposals and quantification of the impacts of greenhouse gas emissions. He has conducted and overseen numerous economic and bill impact assessments in support of projects and policy proposals, ranging from new power plants and transportation facilities to electric, petroleum, and natural gas transmission infrastructure.

Professor Frejinger is an expert in data-driven methods for solving large-scale decision-making problems under uncertainty. Her research, situated within the broad field of AI, focuses on developing mathematical models and algorithms that integrate techniques from econometrics, machine learning, and operations research. Her work has practical applications in areas such as transportation and supply chain management, and addresses challenges that include demand forecasting, pricing, service design, and scheduling. In Professor Frejinger’s deposition testimony and case work, she has drawn on practical and technical experience that includes years spent conducting research and developing bespoke production-grade AI solutions. Professor Frejinger serves as the Canada Research Chair in Data-Driven Optimization for Transportation for the Government of Canada and as the Chair in Optimization of Railway Operations for the Canadian National Railway Company. She is also a member of the Interuniversity Research Centre on Enterprise Networks, Logistics and Transportation, a Canadian interdisciplinary research center. Professor Frejinger is an associate editor of Transportation Science and the INFORMS Journal on Computing. In the AI space, she has served as a scientific advisor to IVADO Labs, an AI solutions provider; as an associate academic member of Mila, an AI research institute; and as a founding fellow of AI Sweden, the Swedish national center for applied AI. Professor Frejinger’s work has received several international awards, including the Transportation Science and Logistics Society’s Dissertation Prize, presented by the Institute for Operations Research and the Management Sciences.

Professor Carlson specializes in the marketing management implications of consumer decision-making processes, including the development of brand preferences and the influence of emerging preferences on the decision making process. Though much of Professor Carlson's research explores consumer decision making, he also studies how voters, jurors, and managers make decisions. Over the last 20 years, he has run thousands of surveys, sampling U.S. and international populations.

Professor Carlson has served as an expert in evaluating a survey in a class action matter, consulted on a high profile class action settlement involving consumer deception, and testified before the SEC in an equity trust matter. Professor Carlson's published research can be found in top marketing, psychology, and management journals. He is also the coauthor of Contemporary Brand Management. He blogs for Psychology Today and Forbes, and maintains an active Twitter account (@ProfKurt). While teaching at Georgetown University between 2009 and 2017, Professor Carlson was director of the Georgetown Institute for Consumer Research and co-director of the McDonough School of Business Behavioral Research Lab, and he received the MSB Dean's Distinguished Faculty Research Award and the Decision Analysis Society's Publication Award.

Mr. Klein has more than 30 years of experience in finance, specializing in private equity, alternative asset management, and investment banking. He has served as a testifying expert in litigation involving clients in the private equity industry and has testified in various arbitration proceedings, as well as in state and federal court. Mr. Klein has extensive experience managing equity and debt investments in private and publicly traded companies. In addition to his position at Ingwe Capital, he provides consulting and senior portfolio advisory services to LyonRoss Capital Management, a family office investment advisor that manages a portfolio of hedge fund and private equity investments in excess of $500 million. Previously, Mr. Klein was a managing director in a principal investments group at Lehman Brothers, where he developed strategies and managed teams of investment professionals that generated approximately $500 million in profits. Following the Lehman bankruptcy, he was a managing director in the Lehman Brothers Holdings private equity group, where he was responsible for managing, restructuring, valuing, and liquidating a $1.8 billion portfolio of illiquid assets. Earlier in his career, as co-founder of Templeton Direct Advisors, an international private equity firm, he helped develop, market, and manage several successful private equity funds exceeding $200 million in committed capital. He has served on the boards of directors for several public and private companies.

Mr. Nguyen performs quantitative analyses and economic modeling in support of complex securities matters. He has consulted on a variety of matters involving investment suitability, investment portfolio valuation and risk analysis, mutual fund excessive fees, ERISA, class certification, and damages. His experience on ERISA-related matters includes evaluations of 401(k) plan investment management and recordkeeping fees, securities lending fees and portfolios, investment option performance, and the appropriateness of selected investment options. Mr. Nguyen has also evaluated target date funds, stable value funds, and managed account products, and has worked on numerous matters related to the investment management of fixed-income portfolios, specifically with regard to investments in mortgage-backed securities and collateralized mortgage obligations. In addition, he has performed numerous valuations of organizations for use in strategic advisory and litigation settings, and has extensive experience constructing, managing, and analyzing large proprietary datasets. His notable case work includes In re: American Funds Fee Litigation; Steve Wildman and Jon Borcherding v. American Century Services, LLC, et al.; Kimberly Davis and Vanessa Romano v. Stadion Money Management, LLC; Leonid Falberg v. The Goldman Sachs Group, Inc., et al.; and Jaime Pizarro, et al. v. The Home Depot, Inc., et al.

Professor Savoldelli is a finance and investment expert with over 25 years of experience analyzing and advising on a wide range of hedge fund-focused issues, including fund performance, portfolio construction, fund administration, due diligence, capital raising, and asset allocation. He served as a chief investment officer for four different institutions: Optima Fund Management, Merrill Lynch, Swiss Bank Corp. Asset Management, and Chase Manhattan Private Bank. In these roles, he oversaw over $80 billion in assets.

Over the course of his investment career, Professor Savoldelli’s responsibilities included selecting hedge funds for the allocation of investor assets, making asset allocation decisions, managing investment portfolios, developing investment policies, and overseeing investment manager adherence to investment strategy and policy. He has deep experience related to the challenging issues hedge fund managers may face, including those related to fiduciary duty, disclosure, liquidation, side-pockets accounts, and valuation of complex and illiquid assets. Additionally, he is knowledgeable about the roles and responsibilities of hedge fund service providers such as prime brokers, marketers, administrators, and auditors.

At Columbia Business School, Professor Savoldelli teaches a course in the M.B.A. program on the investment strategies employed by hedge funds and best practices for the operational aspects of hedge fund management, including fund administration selection, operational risk evaluation, and leverage risk. In addition, he is a contributing editor on Bloomberg Television, commenting on developments from a hedge fund perspective.

Ms. Filsoof has conducted economic and financial analyses and managed case teams in support of academic and industry experts in a broad range of finance and securities, antitrust, and commercial litigation matters. Her finance and securities case work has included examining allegations of securities fraud, evaluating investment compliance and suitability and compliance with fiduciary duties, assessing corporate governance, analyzing investment management fees, analyzing the performance of mortgages and mortgage-backed securities (MBS), and assessing the appropriateness of class certification. Ms. Filsoof has supported industry and academic experts on a variety of topics related to MBS, including due diligence, loan underwriting, appraisal, trustee duties, and damages. She has also supported industry experts in addressing regulatory compliance and banking practices, including issues related to fraud, Bank Secrecy Act (BSA) and Anti-Money Laundering (AML) compliance, third-party lending relationships, and mortgage lending. Ms. Filsoof’s antitrust case work has included analyzing market structure and competitive dynamics, evaluating the competitive effects of mergers, assessing the appropriateness of class certification, and estimating antitrust damages. Her case work has spanned multiple industries, including financial services, insurance, payment cards, high tech, aviation, and pharmaceuticals. She has substantial experience in payments and has supported academic and industry experts in multiple litigation and consulting engagements involving payment cards and emerging payment methods. Ms. Filsoof has provided assistance to attorneys in all phases of the litigation process, including case strategy, discovery, expert reports, deposition, and trial.

Mr. Davis specializes in applying financial economics and data analysis to major litigation matters, with a focus on agricultural markets and pharmaceutical products. He has experience managing case teams, supporting academic affiliates and industry experts, and assisting clients through all phases of complex business litigation, including fact discovery, class certification, merits, trial, and settlement. Mr. Davis’s agricultural experience includes antitrust matters involving allegations of market power in animal protein markets, matters involving the presence of genetically modified products in US grain supplies, and matters involving international trade in agricultural products. His pharmaceutical work includes antitrust matters involving allegations of delayed generic entry, False Claims Act matters involving allegations related to the promotion of pharmaceuticals, and disputes pertaining to the commercial reasonableness of firm conduct.

Mr. Davis also has experience conducting economic research across a variety of industries, including financial services, agriculture, and pharmaceuticals, and analyzing issues related to commodity markets, futures prices, intellectual property and patents, industrial organization and antitrust law, and financial market infrastructure. He is a CFA charterholder. 

Ms. Giacin is a corporate governance and compliance expert with decades of experience advising organizations on whistleblower programs, enterprise risk and crisis management, corporate internal investigations, and ethics and compliance initiatives. She currently serves as an industry consultant, guiding senior leadership on compliance investigations and related analytics, governance frameworks, and risk-tracking systems designed to enhance transparency and stakeholder engagement. Previously, Ms. Giacin was an executive at General Electric and led the company’s Global Ombuds and Open Reporting Programs. In this role, she managed global efforts to promote ethical and safe conduct, ensure legal compliance, and mitigate reputational and operational risks. She oversaw a network of more than 600 ombuds serving hundreds of thousands of employees worldwide and played a key role in resolving thousands of compliance matters annually, involving policies such as fair employment, controllership, conflicts of interest, and environmental health and safety.

Professor Riddiough is best known for his work on real options, mortgage pricing and strategy, REITs, and land use regulation. He has served as an expert in numerous real estate-related matters, in which he has testified on appraisal and the value of distressed mortgages. Professor Riddiough has consulted to numerous organizations, including the US Department of Housing and Urban Development, GMAC, Wells Fargo, Coldwell Banker Commercial, The Equitable Life Assurance Society, and the State of Wisconsin Investment Board. He has published more than 40 scholarly articles. He has served on the boards of directors of several organizations, including ArCap REIT, EquiBase Capital Partners, and the American Real Estate and Urban Economics Association. Professor Riddiough is the recipient of best dissertation and best paper awards in real estate economics, and is a fellow at the Real Estate Research Institute and a past fellow at the Homer Hoyt Institute. He teaches courses in real estate finance, real estate capital markets, and microeconomics.

Dr. Rice is an economist with a range of expertise in health economics, industrial organization, finance, statistics, and econometrics. He has extensive experience applying economic theory and statistical methods in complex litigation and research settings. Dr. Rice has led analyses related to government investigations and litigation matters, where he has supported counsel and served as an expert on alleged False Claims Act (FCA) violations, as well as on antitrust, cryptocurrency, insider trading, misappropriation of trade secrets, and breach of contract issues. In matters related to liability and damages, he conducts empirical analyses involving large-scale databases on a range of topics, including causal inference, merger simulation, and lost profits and budget impact. Dr. Rice’s case experience has involved assisting in the preparation of expert reports, testimony, and rebuttal analyses and arguments; developing sophisticated interactive models enabling real-time damages assessments under alternative scenarios; and presenting analyses to US Attorney’s Office investigators. In addition to his litigation work, he has provided econometric and statistical consulting on matters such as risk management, fair market valuation, and compliance. Dr. Rice is an adjunct faculty member of the Harvard University Department of Economics and has taught undergraduate courses on econometrics, health economics, industrial organization, and regulatory economics. He has published extensively in numerous peer-reviewed journals, and presented at conferences and seminars.

Mr. Case is an institutional investment expert with significant expertise in the areas of investment governance, asset allocation, portfolio design and implementation, and portfolio analysis and reporting. As a former institutional investment consultant, he worked with a wide range of global clients, including insurers, health care organizations, corporate and public plan sponsors, family offices, and other large asset pools. Mr. Case was a partner at Mercer Investment Consulting, a practice leader at Evaluation Associates, and a senior consultant at Rogerscasey. He led client service teams for large clients, including defined-benefit and defined-contribution plans, insurers and mutual fund families, and registered investment advisors and foundations. As an expert, Mr. Case has evaluated various process-related issues, including the process used to monitor an ERISA plan’s investment advisor and delegated fiduciary. He previously worked as an investment analyst for AT&T’s pension investment team, oversaw the sub-advisory and pension assets of AXA Equitable Life, and managed the strategic relationship team at Putnam Investments. He is a CFA charterholder.

Dr. Koehn specializes in applied microeconomics and finance. He has performed research and given economic testimony in antitrust, regulatory, tax, and other business litigation matters. The author of several publications on topics such as banking and finance, energy economics, and real estate, Dr. Koehn is a former adjunct associate professor of finance at the University of California, Irvine Graduate School of Management.

Ms. Fournier, an economist with 20 years of consulting experience, has particular expertise in pharmaceuticals, medical devices, and health economics. She has led case teams and provided analyses in False Claims Act (FCA), Anti-Kickback Statute (AKS), and Racketeer Influenced and Corrupt Organizations (RICO) Act matters, including those involving alleged kickbacks, off-label marketing, misbranding, and pricing issues, among others. She has assisted testifying experts in the preparation of reports, testimony, and related analyses in connection with class certification, liability, and damages. She has also directed economic and statistical analyses for a wide variety of health care-related litigations, including analyses of large datasets and government and private administrative claims records. Ms. Fournier has presented a number of abstracts at health care conferences in the US and Canada and published research on cost of illness, drug cost effectiveness, and other topics in health economics. Her coauthored articles on the economic impact of major depressive disorder have been published in peer-reviewed journals such as the Journal of Clinical Psychiatry and PharmacoEconomics.

Professor Scharfstein is a biostatistician with expertise in the design, monitoring, and analysis of randomized clinical trials and observational studies. His research focuses on methods of reporting the results of clinical studies in which missing or censored data, non-compliance, or non-random treatment assignment may have resulted in selection bias. He has testified at deposition and trial in a number of litigation matters involving drug and medical device safety and efficacy in and outside the US. In addition, Professor Scharfstein regularly consults to the pharmaceutical industry, advising on statistical issues related to the regulatory approval of drugs and medical devices. He has served on multiple data safety monitoring boards for clinical trials, including for the National Institute of Allergy and Infectious Diseases. Professor Scharfstein is the principal biostatistician for the Major Extremity Trauma Research Consortium, which conducts multicenter clinical research studies relevant to the treatment and outcomes of orthopedic trauma sustained in the military. Professor Scharfstein is a fellow of the American Statistical Association, a recipient of the ASA’s George W. Snedecor Award for best paper in biometry, and a recipient of the Harvard T.H. Chan School of Public Health Department of Biostatistics’ Lagakos Distinguished Alumni Award. He has received multiple teaching excellence awards for his classes on probability and statistical theory.

Professor Schoar is an expert in corporate finance, entrepreneurship, and organizational economics. Her research examines returns and capital flows in the venture capital industry, the financing of small- and medium-sized enterprises and startup firms in emerging markets, and the impact of corporate governance practices on firm performance. Professor Schoar has served as an expert witness in cases involving commercial litigation and financial services. She is co-chair of the Corporate Finance Program at the National Bureau of Economic Research and co-founder and scientific director of ideas42, a research lab on behavioral social science. She has published numerous articles and papers and received several awards for her research, including the Ewing Marion Kauffman Prize Medal for Distinguished Research in Entrepreneurship, and the Brattle Group Prize in Corporate Finance for her paper “The Effects of Corporate Diversification on Productivity.” She is the executive editor of The Journal of Finance and previously served as an associate editor of the American Economic Journal: Applied Economics, the Journal of Economic Perspectives, and the Journal of Financial Intermediation. Professor Schoar’s work has been featured in The Economist, the Financial Times, The New York Times, and The Wall Street Journal.

Ms. Glowka is a chartered accountant who specializes in the assessment of damages and forensic analysis arising in the context of dispute resolution. She has served as an expert and led consulting teams on complex UK and international assignments, including litigation and international arbitration matters in all the major international arbitration forums as well as before the High Court of Justice in London, the Scottish Court of Session, and the UK Competition Appeal Tribunal.

Ms. Glowka has acted on a broad range of litigation and arbitration matters across the automotive, oil and gas, pharmaceutical, telecommunications, software, and consumer products industries, among others. Her litigation and arbitration work has involved the evaluation of damages arising in the context of contractual and shareholder disputes, as well as post-transaction disputes such as breach of warranty claims. Ms. Glowka’s forensic accounting work has spanned analysis and tracing of funds and transactions, as well as evaluation of fraud and accounting irregularities, including allegations of accounts manipulation for inflating performance-related bonuses and purchase consideration. She has also evaluated complex financial reporting issues under a variety of accounting standard-setting regimes, including UK generally accepted accounting principles (GAAP) and International Financial Reporting Standards (IFRS). Ms. Glowka is a member of the Institute of Chartered Accountants in England and Wales.

Professor Cawley specializes in the economics of risky health behaviors, particularly those that relate to obesity. His work examines the economic causes and economic consequences of obesity, and the effectiveness of methods of obesity treatment and prevention. He has also researched a variety of topics related to nutrition and harm reduction. Professor Cawley’s publications have appeared in numerous peer-reviewed journals, including the Journal of Health Economics, Health Economics, American Journal of Health Economics, The Lancet, JAMA, Obesity, and Food Policy. He is the recipient of grants from the National Institutes of Health, the Robert Wood Johnson Foundation, and the US Department of Agriculture. His research has been recognized with awards from the Fulbright program, Centers for Disease Control, Robert Wood Johnson Foundation, and Association of University Programs in Health Administration. Professor Cawley is a former editor of the Journal of Health Economics and has served on the Board of Directors of the American Society of Health Economists and the International Health Economics Association. He is an honorary professor of economics at the J.E. Cairnes School of Business & Economics at the University of Galway and a research associate of the National Bureau of Economic Research (NBER).

Mr. Deal leads the economic analyses in the Menlo Park, California office and helps coordinate the firm’s Insurance practice. He combines an economics and risk analysis background with many years of experience in economic, litigation, and management consulting. He serves as a testifying and consulting expert on a wide variety of matters, often involving economic and statistical analysis of large datasets. His work as an expert has covered a variety of practice areas, including antitrust, economic damages, class action matters, and business valuation. Mr. Deal’s experience includes work in health care, insurance, finance, technology, and many other industries. He has coauthored a number of book chapters and studies, including The Economic Effects of Federal Participation in Terrorism Risk with R. Glenn Hubbard, an Analysis Group academic affiliate, former chair of the President’s Council of Economic Advisers, and former dean of the Columbia Business School.

Dr. Rosberg directs complex, data-driven analyses of financial and economic issues for litigation and strategic decisions. He has substantial experience in securities, financial services, antitrust, and corporate governance litigation. Dr. Rosberg’s case work has involved supporting leading experts in high-profile antitrust cases and major securities and investment management cases, including matters involving mutual funds, collateralized debt obligations, and mortgage-backed securities. He has also collaborated with experts in corporate governance cases, including matters involving the appropriateness and impact of board decisions; whether boards have followed acceptable processes in their decision making; and the appropriateness of internal controls. In addition, he has supported experts in two Foreign Corrupt Practices Act (FCPA) cases, Securities and Exchange Commission v. Mark A. Jackson, et al. and United States of America v. Donald J. Carson. Prior to joining Analysis Group, Dr. Rosberg was a management consultant at The Parthenon Group and taught at Dartmouth College and Boston College. His academic work focused on democratization, legal institutions, and human rights in developing countries.

Professor Kothari is an expert on financial reporting and capital markets. His research interests include the measurement of security price performance, the effect of disclosures by management on the equity cost of capital, and the economic determinants of the relationship between earnings changes and stock returns. Professor Kothari also has expertise in valuation, asset allocation, and international accounting practices. From 2019 to 2021, he served as the chief economist and director of the Division of Economic and Risk Analysis at the US Securities and Exchange Commission (SEC). Professor Kothari has provided expert reports and trial testimony, and has consulted to leading US and international banks and asset management companies, US steel companies, Ernst & Young, KPMG, PricewaterhouseCoopers, and the US Department of Justice. He has published articles in peer-reviewed journals such as Management Science, The Accounting Review, and the Journal of Accounting Research. For over 20 years, Professor Kothari served as an editor of the Journal of Accounting and Economics. Previously, he was the global head of equity research for Barclays Global Investors, where he was responsible for research supporting its active equity strategies.

Dr. Garibotti specializes in the application of economics and statistics to questions arising in a variety of settings, including antitrust, finance, and commercial litigation. In her antitrust work, Dr. Garibotti has calculated damages, assessed the appropriateness of class certification, and evaluated allegations of wage fixing, collusive behavior, refusal to deal, exclusive selling arrangements, tying, and non-compete clauses in litigation, in sectors including pharmaceuticals, hospitals, health insurance, auto parts, finance, and technology. She has evaluated market definition, market structure, competitive effects, and efficiencies in merger reviews and investigations. Her work in finance has included cases related to valuation of privately held and OTC-traded companies, payment cards, technology transfer, parking, residential mortgage-backed securities, alleged collusion in financial markets, and investigations of spoofing allegations. Dr. Garibotti has been deposed and provided testimony at trial multiple times, and has provided expert testimony in English and Spanish. She serves as vice chair of the Joint Conduct Committee of the ABA Antitrust Law Section and has participated in webinars and panel discussions on the use of regression in litigation, basics of antitrust economic analysis, two-sided platforms, and cartels.

Mr. Siegel is an expert in financial accounting and has over 30 years of experience as an accounting standard setter, auditor, and equity researcher. His career has focused on enhancing transparency in investor communication channels, both within and beyond regulatory filings. As a director at RiskMetrics Group, Mr. Siegel led a team of more than twenty analysts in the US and London in conducting forensic financial statement analysis designed to detect early warning signs of underappreciated business deterioration. He served as a member of the Financial Accounting Standards Board (FASB) for 10 years and was also a member of the Sustainability Accounting Standards Board (now the International Sustainability Standards Board). In his role at FASB, Mr. Siegel was instrumental in the areas of financial statement presentation, financial performance reporting, and disclosure framework. He also served on the FASB Investors Technical Advisory Committee. Mr. Siegel has authored numerous articles on accounting topics and was a frequent guest on CNBC and a variety of financial television programs. In addition to founding Metrix Advisory, he is currently a senior advisor at Alvarez & Marsal’s Global Transaction Advisory Group and an executive in residence at Fordham University’s Gabelli School of Business. A certified public accountant, Mr. Siegel, who has been a partner with EY and PwC, started his career in audit and litigation support at Arthur Andersen.

Mr. Decter specializes in the application of microeconomics, finance, and data analysis to complex securities and antitrust litigation and business strategy cases, most notably in matters related to residential mortgage-backed securities, collateralized debt obligations and credit default swaps, residential mortgage lending, mortgage reinsurance, commercial insurance, private equity, and payment cards. He has conducted damages analyses, and supported multiple experts in the areas of statistical sampling, loan and securities underwriting, damages, and loss causation.

Mr. Decter's business litigation experience focuses on finance matters in which he has managed large case teams and data sets in working with testifying experts. He supported academic affiliates in their examination of class certification issues related to commonality, predominance, and causation in In re Countrywide Financial Corp. Mortgage Marketing and Sales Practices Litigation, a mortgage marketing matter in which the plaintiff's motion for class certification was denied. Mr. Decter also supported an expert in filing a report on behalf of the defendants in New Jersey Carpenters Vacation Fund et al. v. The Royal Bank of Scotland Group plc et al., a case that marked the first major ruling on class certification among the numerous mortgage-backed securities actions pending in courts across the country at the time. He has also conducted damages analyses and worked with experts in numerous securities, antitrust, and intellectual property cases. Mr. Decter's business strategy engagements related to strategic pricing, portfolio management, and economic cost studies have spanned multiple industries, including pharmaceuticals, telecommunications, information technology, and manufacturing.

Prior to joining Analysis Group, Mr. Decter was a management consultant in the telecommunications industry. He also has several years of telecommunications industry experience in strategic planning, business development, and product management. 

Professor Snyder is an industrial organization economist whose research focuses on antitrust policy and enforcement, contracting practices, financial institutions, and law and economics. He has consulted on and served as a testifying expert in numerous high-profile cases, opining on liability, damages, proposed mergers, price-fixing allegations, Hatch-Waxman claims involving pharmaceuticals, monopolization claims, and proposed class certifications of both direct and indirect purchasers. In addition, Professor Snyder has testified before combined US Federal Trade Commission (FTC) and US Department of Justice (DOJ) hearings on competition and intellectual property, and has presented separately before the DOJ’s Antitrust Division, where he worked as an economist earlier in his career, and the FTC. He has been a signatory to amicus briefs submitted to the Supreme Court on various price-fixing and Sherman Act issues.

Professor Snyder has written extensively on topics related to antitrust and policy issues, with his articles appearing in prestigious publications such as The Journal of Law and Economics, the Journal of Comparative Economics, The Antitrust Bulletin, and Contemporary Policy Issues. His work has also been featured in major media outlets, including the Financial Times, The Wall Street Journal, and The New York Times.

Professor Snyder also served as the dean of the Yale School of Management from 2011 to 2019, during which time he enhanced the school’s academic programs and financial standing, and established new master’s programs in the areas of management, entrepreneurship, and executive education. He also founded the Global Network for Advanced Management at Yale University, an international consortium of schools devoted to teaching tomorrow’s business leaders around the world. Prior to joining Yale, Professor Snyder was the dean of the business schools of The University of Chicago, the University of Virginia, and the University of Michigan.

Professor Haas-Wilson is an expert in health care antitrust, including the competitive effects of hospital mergers and commercial health insurer mergers, the effects of vertical consolidation in health care markets, and the implications of physician networks on competition in the health care industry. She recently testified in Federal District Court in Idaho on behalf of plaintiffs, in an antitrust lawsuit alleging competitive harm from St. Luke’s Health System’s acquisition of a large independent physician practice. She has served as a consultant on antitrust issues to the Federal Trade Commission, the Massachusetts Attorney General, the California Department of Corporations, and numerous private entities. She also testified on behalf of the Federal Trade Commission in the matter of Evanston Northwestern Healthcare Corporation. Professor Haas-Wilson is the author of Managed Care and Monopoly Power: The Antitrust Challenge and coeditor of Uncertain Times: Kenneth Arrow and the Changing Economics of Health Care. Her research has appeared in the Journal of Political Economy, the Journal of Economic Perspectives, the Journal of Law and Economics, the Review of Economics and Statistics, and the Journal of Health Economics, among others.

Dr. Rothman specializes in the economic analysis of antitrust and competition issues. He has been retained by multiple private parties to present analyses to the US Department of Justice (DOJ) and US Federal Trade Commission (FTC) and has been retained by and testified for the DOJ and FTC as an expert witness in multiple merger matters. He has also supported economic experts on multiple merger matters on behalf of the DOJ, FTC, and merging parties. In addition to his merger work, Dr. Rothman has worked on multiple joint conduct and unilateral conduct matters.

Dr. Rothman is a senior editor of the Antitrust Law Journal. He has published research in outlets including Antitrust Law Journal, The Antitrust Source, Journal of Health Economics, Journal of Competition Law & Economics, and Concurrences: Competition Law Journal. Dr. Rothman has taught a course on the economics of merger analysis in the economics department at Harvard University. Prior to joining Analysis Group, he was an assistant professor at Columbia University.

Professor Chalmers is an expert in securities issues, including the trading behavior of investors and the pricing of securities. He has undertaken extensive research in municipal bonds, mutual funds, and trading costs, much of which has been published in leading peer-reviewed academic journals, including The Journal of Finance, the Journal of Financial Economics, and The Review of Financial Studies. In the area of mutual funds, his research with Professors Roger Edelen and Greg Kadlec discovered and explained the source of perverse incentives exploited by so-called market timers in their trading of mutual funds. He has also written about stale pricing problems in equity mutual funds and mutual fund transaction costs, and has collaborated with other mutual fund experts, such as Professors Daniel Bergstresser and Peter Tufano, on research analyzing fund performance across fund marketing channels. He also has extensive expertise in municipal bond pricing and valuation issues. Professor Chalmers' research has been cited in reports by the General Accounting Office and in several testimonies provided before the House Financial Services Committee, as well as being widely referenced in major media outlets. He has authored several expert reports and provided testimony before the US District Court of Wisconsin.

Dr. Ginn specializes in applying economic and statistical techniques to construct complete analyses in both litigation and non-litigation contexts. She has led large teams in antitrust cases in several industries, including technology, chemicals, telecommunications, finance, pharmaceuticals, and agricultural products. Her recent work has focused on alleged anticompetitive practices by big tech firms and alleged class-wide horizontal price-fixing conspiracy cases, including benchmark interest rates and consumer products. Dr. Ginn’s experience also includes evaluations of alleged patent and copyright infringements in the pharmaceutical and entertainment industries, merger analysis, and responding to inquiries from domestic and international competition authorities. She has served as an economic expert in matters requiring statistical and technical expertise and has worked on several strategy cases in the technology and pharmaceutical industries.

Dr. Kupiec’s research interests include quantitative financial risk measurement, systemic risk, deposit insurance, and the regulation of banking and financial services. At the American Enterprise Institute, he has authored several studies on systemic risk measurement and related regulations, bank stress testing, and bank regulations that follow financial crisis, including their impact on the wider economy. Dr. Kupiec was an associate director of the Division of Insurance and Research and director of the Center for Financial Research (CFR) at the Federal Deposit Insurance Corporation. In these roles, he oversaw research on bank risk measurement that contributed to the development and implementation of regulatory policies, including the international Basel III framework. He also served as chairman of the Research Task Force of the Basel Committee on Banking Supervision. Dr. Kupiec has worked at the International Monetary Fund, Freddie Mac, and J.P. Morgan, as well as for the Division of Research and Statistics at the Board of Governors of the Federal Reserve System. Prior to entering the financial services industry, Dr. Kupiec was an assistant professor of finance at North Carolina State University. He has published articles in several academic journals, including The Journal of Finance, the Journal of Financial Intermediation, the Journal of Financial Stability, the Journal of Financial Services Research, The Journal of Risk, and the Journal of Investment Management.

Dr. Siegel's research focuses on the management, strategy, and organizational issues related to cybersecurity, the intelligent integration of information systems, risk management, data analytics, state stability, systems modeling, security of energy delivery systems, and security researchers (aka hackers). He has served as an expert witness and filed expert reports in a number of IT-related litigations for clients such as SAP, JPMorgan, IBM, Kenexa, Fisher Scientific, Ernst & Young, and Macromedia. His expert case work includes matters involving the acquisition of a software firm, software patent litigation and review (e.g., the Patent Trial and Appeal Board case Versata v. SAP), patent infringement and validity analysis, software licensing agreement disputes, and matters involving financial services software and software related to the extraction of data from web pages. Dr. Siegel has published articles on such topics as simulation modeling for cyber resilience, cyber vulnerability markets, data management strategy, architecture for practical metadata integration, heterogeneous database systems, and managing and valuing a corporate IT portfolio using dynamic modeling of software development and maintenance processes. 

Dr. Chan is a practicing internal medicine physician and an economist. His research draws on industrial organization, labor economics, and applied econometric principles to study how technology and information are used in health care, and how they affect productivity and patient care. Dr. Chan’s government service includes roles as entrepreneur in residence in the White House Office of Science and Technology Policy, staff fellow in the Food and Drug Administration’s (FDA’s) Center for Drug Evaluation and Research, and medical device fellow in the FDA’s Center for Devices and Radiological Health. He has published on health economics and policy in medical and economics journals such as The New England Journal of Medicine, the Journal of Political Economy, Econometrica, and The Quarterly Journal of Economics. Dr. Chan presents frequently at national and international conferences and has received numerous grants and awards, including the National Institutes of Health Director’s High-Risk, High-Reward Early Independence Award, and a Marshall Scholarship. He is a faculty research fellow at the National Bureau of Economic Research. Dr. Chan is also co-director of the US Department of Veteran Affairs Queri Center for Policy Evaluation.

Mr. Egland has worked on a wide range of assignments related to litigation, internal corporate consulting, and government investigations for over 35 years. He specializes in financial economics, statistical sampling, and the economics of competition. Mr. Egland directs the firm’s risk management practice, which provides comprehensive risk audits of investment portfolios. He has presented Analysis Group’s work to government regulatory agencies, to corporate boards, and in court. He has led several teams evaluating claims of excessive fees in the mutual fund industry and on ERISA cases involving the reasonableness of fees charged to 401(k) plan participants. In addition, Mr. Egland has worked on several studies assessing the risk profiles of investment portfolios. In Florida State Board of Administration v. Alliance Capital Management, he led a case team that supported six external experts in a landmark trial victory, in which a Florida jury found Alliance Capital not liable for the losses incurred by the Florida Retirement System pension fund as a result of Alliance Capital’s investments in Enron stock. He also led a case team on behalf of American Century Investments in one of the largest mutual fund excessive fee actions ever filed, which was voluntarily dismissed by the plaintiffs before trial. Mr. Egland is a CFA charterholder.

Professor Happe is a licensed pharmacist with more than 20 years of experience as an academic and a senior executive across health care consulting, pharmaceutical research, managed care, and graduate education. Her areas of expertise include pharmacy benefit management, drug coverage policy, pricing and payment flows throughout the supply chain, pharmacoeconomics, health outcomes research, and epidemiology. Prior to joining the University of Florida, Professor Happe was the chief pharmacy officer at Humana Pharmacy Solutions, where she directed the outcomes research and policy teams and led the enterprise opioid task force. She also served as Humana’s director of research and publications, contributing to more than 70 articles published in peer-reviewed journals. Professor Happe is editor in chief of the Journal of Managed Care & Specialty Pharmacy.

Dr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.

Professor Laby is an expert in corporate law, securities regulation, the regulation of investment management, and the fiduciary obligation. He has been retained as a consultant and expert witness, and he has testified in federal and state court, in arbitration hearings, and in Securities and Exchange Commission (SEC) administrative proceedings in matters involving issues such as investment suitability, fiduciary duty, the roles and responsibilities of broker-dealers and investment advisors, and conflict-of-interest transactions. Professor Laby has also opined on corporate law topics such as directors’ duties, insider trading, and piercing the corporate veil. He is coauthor of a multi-volume treatise titled The Regulation of Money Managers: Mutual Funds and Advisers. He has published book chapters and articles on topics such as the regulation of financial firms, the regulation of retirement advisors, and the duties and obligations of financial market participants in publications such as the Washington Law Review, the Florida Law Review, the Boston University Law Review, the Tulane Law Review, the Review of Banking and Financial Law, and The Business Lawyer. Professor Laby is a co-director of the Rutgers Center for Corporate Law and Governance and a director of the Japan Smaller Capitalization Fund, a closed-end management investment company listed on the NYSE. He previously served on the board of directors of the Certified Financial Planner Board of Standards, as chairman of the board of trustees of the SEC Historical Society, and as a member of an American Bar Association (ABA) task force that prepared the fourth edition of the ABA Fund Director’s Guidebook. Before joining the Rutgers faculty, Professor Laby served as SEC assistant general counsel, where he was responsible for investment management and international matters, and was in private practice.

Ms. Guérin is a health economist specializing in health economics and outcomes research (HEOR) and real-world evidence. She designs and leads retrospective database studies (claims, electronic health records, registries, and unstructured physician notes), large-scale multi-country chart reviews and surveys, and economic models to inform clinical, policy, and market-access decisions. She has deep expertise in data curation, linkage, and quality assessment across disparate datasets, and applies advanced statistical methods to generate robust, credible evidence. Her methodological work spans comparative and cost effectiveness, patient-reported and preference research, burden of illness, treatment patterns, safety analyses, and predictive modeling, using machine learning and AI to advance risk prediction, patient stratification, treatment optimization, and early identification of unmet needs.

Therapeutic experience includes oncology, hematology, hepatology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology, and respiratory disease. Ms. Guérin leads HEOR strategy and global evidence generation planning for biopharmaceutical partners, supporting both regulatory (US Food and Drug Administration (FDA) and European Medicines Agency) and payer decision making through value communication materials. She is recognized for developing international, large-scale evidence-generation strategies that balance scientific rigor with real-world feasibility. Ms. Guérin has authored over 100 peer-reviewed publications, frequently presents at scientific conferences, and contributes to advancing HEOR and real-world evidence methodologies.

Professor Simonson is an expert in survey methods, behavioral decision making, buyer behavior, consumer evaluation of brands and promotional offers, and marketing management. His research includes experimental studies on the effect of survey methods on likelihood-of-confusion estimates and examines topics such as how consumers make product choices in the digital marketplace, how information gleaned from customer surveys can be misleading, and how consumer decision making impacts marketing practices. Professor Simonson has served as an expert witness in matters involving surveys, trademarks, buyer behavior, the impact of product and service features on buyers’ choices, false advertising, branding, and other marketing issues. He has consulted to clients in a wide range of industries. He is a coauthor of the book Absolute Value: What Really Influences Customers in the Age of (Nearly) Perfect Information.

Professor Simonson has also published numerous articles on topics such as the impact of product features, product and service evaluations, trademark confusion, buyer decision making, and survey methods. His research has won many awards, including two O’Dell awards for research that has made a “significant, long-term contribution” to the field of marketing. Professor Simonson is also a lifetime fellow of the Association of Consumer Research for his impact on the scholarly study of consumer behavior. He received an honorary doctorate from the University of Paris II (Sorbonne Universities). He serves on the editorial boards of several leading publications and is the coeditor of Consumer Psychology Review. At Stanford, Professor Simonson has taught M.B.A. courses on marketing management, marketing to businesses, technology marketing, and applied behavioral economics, as well as Ph.D. courses on buyer behavior, surveys, consumer research methods, and behavioral economics.  

Mr. Ellman specializes in the application of microeconomics, statistics, and financial analysis to complex commercial litigation matters and government investigations. He has worked on behalf of the US Department of Justice and Federal Trade Commission, and has consulted to law firms in litigation and regulatory matters involving antitrust and competition, drug safety and product liability, intellectual property, data breaches, and general commercial damages issues. Mr. Ellman has conducted market analyses and assessments of competitive effects in major antitrust matters, as well as for proposed and executed mergers. He has also conducted statistical analysis, market research, and other economic analyses to evaluate the appropriateness of class certification in antitrust and commercial disputes, and to assess liability and damages. Mr. Ellman’s expertise in matters involving the pharmaceutical and medical device industries includes analyzing therapeutic markets and competitive dynamics; assessing evidence of causal associations in product liability suits; and conducting statistical analyses of market surveillance, clinical trial, and observational study data to evaluate the comparative effectiveness, safety, and dosing patterns of different treatments across a variety of therapeutic categories. He has published articles on a wide range of topics, including the assessment of causation and harm in data breach litigation, the appropriate analysis and interpretation of post-marketing surveillance data in product liability cases, and the economics of biosimilar drugs.

Professor Tucker is an industrial organization economist whose research spans the fields of technology, health care, real estate, and media and advertising. A particular focus of her work is on the role of data and digitization on competition and consumer behavior. Professor Tucker has deep experience as an expert witness in a variety of cases spanning antitrust and competition, intellectual property, data and data privacy, online advertising, and digital platforms. She has assessed market definition, competitive effects, liability, and class certification issues in matters involving pharmaceuticals, health insurance, consumer goods, sports and entertainment, energy, and consumer electronics, among other industries. She has testified about the effects of data, privacy, and algorithms before Congress, and has presented her work to agencies and organizations such as the Federal Trade Commission (FTC), the Federal Communications Commission (FCC), the International Monetary Fund (IMF), the European Commission Directorate-General for Competition (DG COMP), and the Australian Competition and Consumer Commission (ACCC).

Professor Tucker has published widely on innovation and technology diffusion; online advertising, customer heterogeneity, and algorithms; privacy regulation; network effects; and the economics of social networks. At the National Bureau of Economic Research (NBER), she serves as a research associate, focusing on privacy; a principal investigator on the Project on the Economics of Digitization; and a co-organizer of the Economics of Artificial Intelligence initiative, supported by the Alfred P. Sloan Foundation. Professor Tucker is a co-founder of the MIT Cryptoeconomics Lab, which studies digital currencies and blockchain, and chair of the MIT Sloan Ph.D. Program. Her articles have appeared in leading scientific, economic, management, and marketing journals. She has previously served as associate editor of Management Science and the Journal of Marketing Research and coeditor of Quantitative Marketing and Economics, and she is currently senior editor of Marketing Science.

Professor Chandra focuses his research on innovation, productivity, and cost growth in health care; medical malpractice; and racial disparities in medical care. He has testified before the US Senate and the US Commission on Civil Rights and served as a special commissioner on the Massachusetts Special Commission on Provider Price Reform. Professor Chandra is a member of the Congressional Budget Office’s panel of health advisors, a research associate at the National Bureau of Economic Research, and an elected member of the American Academy of Arts and Sciences, the National Academy of Medicine, and the National Academy of Social Insurance. His research has been published in American Economic Review, the Journal of Political Economy, The Quarterly Journal of Economics, The New England Journal of Medicine, JAMA, Health Affairs, and other professional journals. Professor Chandra has received several awards for his work, including the Kenneth J. Arrow Award for best paper in health economics, the Garfield Award for outstanding research on the economic impact of medical and health research, the National Institute for Health Care Management Foundation Health Care Research Award, and the American Society of Health Economists’ ASHEcon Medal.

Dr. Schatzki is an economist with expertise in markets and regulated industries, particularly energy markets and regulation. Within the energy sector, his expertise includes market design, finance, competition, ratemaking, market impacts, and benefit-cost analysis in the electricity, natural gas, petroleum, and renewable energy sectors. Dr. Schatzki supports clients in a range of contexts, including regulatory and rulemaking proceedings, litigation, policy analysis, and strategic and financial advice.

His expertise in the electricity sector includes wholesale electricity market design; market conduct and competitive analysis; financial analysis, including valuation and cost of capital; utility regulation and ratemaking; economic analysis of new market rules, regulations, and infrastructure investments; and contract analysis and disputes. His clients include electricity system operators, market monitors, generation, transmission and distribution companies, government agencies, and non-government agencies. Dr. Schatzki has testified before US state and federal, as well as Canadian provincial, regulatory commissions. He has also provided testimony at bankruptcy court and arbitration.

Dr. Schatzki has worked extensively on environmental economics, policy, and regulation, with his recent work focusing on the intersection of climate policy and energy markets, and disputes involving water resources and environmental contamination. His research has been published in distinguished energy- and environment-related publications, and he has provided research for prominent organizations such as the Electric Power Research Institute, the Edison Electric Institute, and the Federal Energy Regulatory Commission.

Ms. Hauert is a regulatory expert who specializes in the electric and water utility industries. She has served as an expert witness in rate cases and provided expert testimony for matters before the Arizona Corporation Commission and the Federal Energy Regulatory Commission. In her role at Hauert Consulting, Ms. Hauert draws on her nearly two decades of utility experience to provide strategic consulting services to regulated utilities, including preparing rate cases and rate design, cost-of-service studies, and surcharges. She previously served as vice president of rates and revenues at Arizona Water Company, where she led a $90 million cost recovery strategy and facilitated the acquisition of three small water utilities. Ms. Hauert also held roles at Arizona Public Service, where she oversaw a $3 billion cost recovery strategy and developed a multiyear corporate strategic playbook. She is currently the executive director of the Water Utilities Association of Arizona.

Ms. Hunt has more than a decade of experience applying economics, finance, and accounting concepts to a variety of litigation topics, including commercial disputes, M&A, and securities and derivative instruments. Her experience spans a wide variety of sectors and has included fact and expert discovery, class certification, liability and damages, and trial. Ms. Hunt has supported academic affiliates and industry experts in matters related to startups, private equity, and venture capital, involving analyses of future fund performance, evaluation of practices related to fundraising and investor relations, and assessment of novel business strategies for new entrants. Her work has included assessing damages and quantifying potential litigation exposure, assessing the risk quantification and investment strategies of investors, and evaluating buy-side and sell-side due diligence processes in mergers and M&A. Ms. Hunt has also assisted experts in matters involving corporate governance, the appropriateness and impact of board decisions, and whether boards have followed acceptable decision-making processes.

Read Lauren's profile

Professor Skrzypacz is an expert in industrial organization and market design. His research centers on microeconomic theory and its applications, including collusion, auctions, pricing, and bargaining. In addition to his academic research, Professor Skrzypacz consults on auction strategy and competition issues, and has served as an academic visitor at Yahoo! Research. He has counseled bidders in wireless spectrum auctions in the United States, Canada, the Netherlands, Switzerland, Austria, and Sweden. He has also advised internet companies on design and competition in online auctions, and communication companies on regulation issues.

Professor Skrzypacz has published a number of articles on topics such as using spectrum auctions to enhance competition in wireless services, private monitoring and communication in cartels, and information disclosure. His most recent papers have focused on auction design, dynamic games, and collusion in markets. He is an associate editor of The RAND Journal of Economics and American Economic Review: Insights, and a former coeditor of American Economic Review. Additionally, Professor Skrzypacz is a fellow of the Econometric Society, an economic theory fellow of the Society for the Advancement of Economic Theory, and a senior fellow of the Rimini Centre for Economic Analysis.

Ms. Hitscherich specializes in corporate acquisitions, leveraged buyouts, exclusive sales and divestitures, takeover defenses, and restructurings. She has served as an expert witness in several complex securities litigations, including matters involving deal structure, valuation, due diligence, custom and usage in the finance industry, and financing alternatives.

Ms. Hitscherich has extensive experience in investment banking and corporate law practice, including as a managing director in mergers and acquisitions with Banc of America Securities, where she was secretary of the Fairness Opinion Review Committee; vice president in mergers and acquisitions with J.P. Morgan & Co., where she was a founding member of the takeover defense team and a senior member of the acquisitions fairness Advisory Review Committee; and as a mergers and acquisitions attorney with Skadden, Arps, Slate, Meagher & Flom.

Dr. Signorovitch advises life sciences companies on data analytics for business critical research and decision making. He has broad experience leading the strategic development and implementation of analytics across the product life cycle, from early-phase clinical studies to market access and real-world evidence generation. Dr. Signorovitch’s practice areas span trial design, multi-stakeholder collaborations, natural history studies, regulatory interactions, health economic modeling, global reimbursement submissions, policy evaluation, real-world evidence development, individualized medicine, predictive analytics, and due diligence for acquisitions. He has particular expertise in developing and applying new methodologies to address health care research challenges, and in designing analytics platforms to enhance collaborative research and decision making. Dr. Signorovitch’s work has been used to inform clinical regulators and health care payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology. 

Professor Tufano’s work spans a broad range of topics in finance, including climate finance and derivatives and structured finance. His research interests include financial innovation, business solutions to climate change, the design of new securities and financial instruments, the organization of financial markets, corporate risk management, the mutual fund industry, and household finance. Professor Tufano has provided expert testimony and reports in several finance- and securities-related matters, including a matter involving retained asset accounts; the Parmalat securities litigation; economic characterizations of securities for tax courts; and the Enron Corporation securities, derivative, and ERISA litigations.

He has written a number of books, and his articles have been published in journals such as The Journal of Finance, the Journal of Financial Economics, The Review of Financial Studies, and Harvard Business Review. He is an associate editor of the Journal of Investment Management. Professor Tufano’s work has also been featured in a number of media outlets, including The New York Times and the Financial Times. He has received several awards, including the Smith Breeden Prize for the best finance paper published in The Journal of Finance and a leadership award from the Aspen Institute. Prior to re-joining the Harvard Business School faculty, he was dean of the Saïd Business School at the University of Oxford for a decade.

Mr. Chen is an expert in structured finance with two decades of experience and product expertise in asset-backed securities and other structured products. These include collateralized debt obligations (CDOs), collateralized loan obligations (CLOs), derivative product companies (DPCs), asset-backed securities (ABS), residential mortgage-backed securities (RMBS), and structured investment vehicles (SIVs). Mr. Chen has served as a testifying expert on issues related to CLO, CDO, and RMBS ratings. He has provided management consulting and litigation support on securities and derivatives matters involving commercial and residential real estate, credit derivatives and total return swaps, and interest rate derivatives and indices, such as the London Interbank Offered Rate (LIBOR) and the transition from LIBOR to the secured overnight financing rate (SOFR). Prior to founding Pronetik in 2010, Mr. Chen was the chief operating officer (COO) and managing director at Centerline Financial LLC. There he monitored synthetic portfolios of multifamily and commercial real estate transactions, drafted and negotiated credit default swap documentation, and served as chief liaison with rating agencies. Earlier in his career, Mr. Chen was vice president of the structured finance-derivatives group at Moody’s Investors Service, where he rated transactions including cash flow and synthetic CDOs, structured notes, credit linked notes, and catastrophe (cat) bonds. He began his career as an associate at Willkie Farr & Gallagher, then joined Sullivan & Cromwell with a practice in corporate law, securities, and a concentration in structured finance. Mr. Chen has appeared on the CBS Evening News and been quoted or cited in media including The Wall Street Journal, Bloomberg News, and Businessweek.

Mr. Feige specializes in the areas of finance, securities, and financial markets. He has worked on and managed a range of securities and valuation projects in the UK and Europe. Mr. Feige has been appointed as expert in Dutch court to provide valuation and securities claims reports in support of Steinhoff’s global securities settlement, and gave evidence in the Dutch Enterprise Chamber regarding the valuation of Getir. He has also managed teams evaluating shareholder reliance and disclosure materiality and estimating counterfactual share prices in UK Financial Services and Markets Act (FSMA) Section 90A litigation matters. Mr. Feige has supported experts analyzing the volume of false and spam accounts on Twitter, Twitter’s information security infrastructure, Twitter’s data privacy and compliance with a US Federal Trade Commission (FTC) consent decree, and share price and valuation issues on behalf of Twitter in Twitter v. Musk in which Elon Musk eventually purchased Twitter at his initial offer price. In cases involving alleged market manipulation in the foreign exchange (FX) and IBOR markets, he has analyzed trade data and evaluated alleged manipulation strategies. Mr. Feige worked on USA v. Richard Usher, et al., and the Foreign Exchange Class Antitrust Litigation, analyzing FX trade and chat data, as well as competition issues; preparing experts for testimony at trial; and providing data analyses and consulting support to counsel throughout the projects. He has also worked on a range of international arbitration cases, including valuation, damages, and competition analyses. In addition, he has developed complex valuation models, including discounted cash flow models, and analyzed asset-backed securities, collateralized debt obligations, and other securitized products in support of expert testimony in a number of bankruptcy and damages matters. Mr. Feige has also worked on a number of international arbitrations valuing defaulted sovereign debt, expropriated oil fields, and retail operations. His work has been published in several industry journals.

Mr. Lakhani specializes in accounting and auditing, with a focus on life science and technology companies. He has testified before the US Securities and Exchange Commission (SEC), Public Company Accounting Oversight Board (PCAOB), and the US Department of Justice; and has supervised whistleblower investigations in accordance with PCAOB standards and SEC regulations. He has also served as an accounting expert and testified in federal bankruptcy court. Previously, Mr. Lakhani was a senior partner with Ernst & Young (EY), where he led the national professional practice group for the western US. In this role, Mr. Lakhani consulted on accounting, auditing, and SEC filing and reporting matters with Fortune 500 clients. He was elected to serve on the firm’s board of partners, its highest governance and oversight body. While working at EY, Mr. Lakhani was a lead partner for the biotech company Amgen and the pharmaceutical company Allergan. He has served as an independent review partner for Fortune 500 companies, and he is a former member of InTouch Health’s board of directors and the chairman of its audit committee. Mr. Lakhani is a certified public accountant licensed in California.

Ms. Kindler is an economist with extensive experience in a variety of engagements, including intellectual property disputes, contract disputes, litigation matters related to securities and finance, false advertising allegations, class action disputes, and antitrust matters. She has testified numerous times in deposition, trial, and arbitration and assisted in all phases of the litigation process, including discovery, expert reports, deposition, and trial preparation. With respect to intellectual property disputes, Ms. Kindler has evaluated damages in the context of allegations of patent infringement, trade secret misappropriation, trade dress infringement, and copyright infringement. In patent infringement matters, she has analyzed claimed lost sales, claimed lost profits, and reasonable royalty damages. She also has evaluated disgorgement and actual harm in the context of numerous intellectual property disputes. Ms. Kindler has been involved in numerous licensing negotiations relating to a wide range of technologies and products, including but not limited to standard essential technology, software, smartphone and wireless technologies, dental implants, and oil and gas. In class action disputes, Ms. Kindler has evaluated both class certification and damages issues. In antitrust matters, she has assessed the competitive consequences of mergers, analyzed the competitive behavior of market participants, estimated the impact of market power, and evaluated damages. Her work has also included the development of complex damages models, the analysis of statistical data, and the analysis of stock price movements. Prior to joining Analysis Group, Ms. Kindler held positions with two economics consulting firms.

Professor Snow is an expert in technology and operations, innovation management, and service management, with a specialization in automotive, health care, aerospace, and growth-stage companies. His research addresses two areas: the complex relationship between new and old technologies during technology transitions; and service operations, particularly the building of theoretical microfoundations to help define the field, and empirical research on operational productivity. Professor Snow has testified in antitrust and competition cases as well as commercial disputes. He has taught at Harvard Business School, The Wharton School of the University of Pennsylvania, Tuck School of Business at Dartmouth College, and BYU Marriott School of Business; presented at a variety of management, innovation, and technology conferences; and written numerous cases for academic use. In 2014, he and coauthor Lamar Pierce received the Olin Award for Research That Transforms Business. Professor Snow is an executive committee member of the Harvard Business School Institutions and Innovation Conference, and a former board member of the Council of Supply Chain Management Professionals.